Pneumonia Newswire

Pneumonia Newswire

Comprehensive Real-Time News Feed for Pneumonia.

Results 1 - 20 of 656 in Pneumonia

  1. Shifting trends in bacteriology and antimicrobial resistance among...Read the original story w/Photo

    Wednesday | BioMed Central

    ... to have experienced cancer. Over the entire study period, most infections were caused by E. coli (24.2%) and K. pneumonia (14.1%). There was a significant decrease in the proportion E. coli isolates that were extended- spectrum beta-lactamase ...

    Comment?

  2. Nabriva Looks To Another Phase 3 To Seal The DealRead the original story w/Photo

    13 hrs ago | Seeking Alpha

    Another phase 3 catalyst is expected to be read out in Spring of 2018, testing oral lefamulin against oral Moxifloxacin. Nabriva Therapeutics had an outstanding day on Monday because it reported positive phase 3 results in patients with community-acquired bacterial pneumonia .

    Comment?

  3. Notes from the Field: Travel-Associated Melioidosis and Resulting...Read the original story w/Photo

    13 hrs ago | Centers for Disease Control and Prevention

    ... Burkholderia pseudomallei , the causative organism of melioidosis, on August 30. The patient did not experience pneumonia or bacteremia, and recovered fully after 2 weeks of intensive therapy with parenteral ceftazidime and a 6-month outpatient ...

    Comment?

  4. Paratek Release: Omadacycline Receives Qualified Infectious Disease...Read the original story

    Wednesday | BioSpace

    ... Omadacycline has previously been granted QIDP designation for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI) and complicated urinary tract infections (cUTI). "Omadacycline ...

    Comment?

  5. Nabriva Therapeutics Announces Positive Topline Results from Global,...Read the original story w/Photo

    Sunday Sep 17 | Drugs.com

    Nabriva Therapeutics plc , a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced positive topline results from the lefamulin evaluation against pneumonia trial, which evaluated the safety and efficacy of intravenous to oral lefamulin in patients with community-acquired bacterial pneumonia . CABP is the leading cause of infectious death in the United States.

    Comment?

  6. Paratek To Host Investor Day On October 17, 2017Read the original story

    Tuesday Sep 19 | BioSpace

    ... for the treatment of serious community-acquired bacterial infections, including community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections. Omadacycline has been granted ...

    Comment?

  7. Ventilator-Associated Pneumonia (VAP) Market 2027 - Nabriva...Read the original story w/Photo

    Tuesday Sep 19 | SBWire

    Market Research Future adds new report of "Global Ventilator-associated pneumonia Market Research Report- Forecast To 2027" it contains Company information, geographical data and Table of Content Competitive Analysis: Some of the key players in this market are: - Merck & Co., Inc. - Adenium Biotech ApS - AstraZeneca - MedImmune - Nabriva Therapeutics AG Intended Audience - Ventilator-associated pneumonia manufacturers - Ventilator-associated pneumonia Suppliers - Pharmaceutical companies - Research and Development Companies - Medical Research Laboratories - Academic Medical Institutes and Universities Get a Sample Report @ Market Segments: Global Ventilator-associated pneumonia market has been segmented - On the basis of Diagnosis; this includes clinical, radiological, and microbiological - On the basis of End Users; this consists ... (more)

    Comment?

  8. Rural doctor sets superbug exampleRead the original story w/Photo

    Monday Sep 18 | The Telegraph

    ... the greatest abuse of antibiotics," Ramaiah said. "Neonates are so fragile. And respiratory infections leading to pneumonia are among the biggest threats to neonates in intensive care units. Doctors sometimes take quick decisions on antibiotics out ...

    Comment?

  9. Why Nabriva Therapeutics PLC Is SkyrocketingRead the original story w/Photo

    Monday Sep 18 | The Motley Fool

    Shares of the clinical-stage biotech focused on antibiotics rose 36% as of 11:30 a.m. EDT on Monday in response to reporting encouraging data from its phase 3 LEAP 1 trial. The LEAP 1 trial was designed to study the safety and efficacy of the company's lead compound lefamulin in treating community-acquired bacterial pneumonia .

    Comment?

  10. Liberia: Harvard Doctor to Save Million Lives in LiberiaRead the original story w/Photo

    Monday Sep 18 | AllAfrica.com

    ... healthcare workers with real life-saving skills, whether that's giving vaccines or testing for malaria or treating pneumonia. In a single backpack, the worker has the tools and medicines to employ 30 different life-saving services, Panjabi said. ...

    Comment?

  11. Melinta Publication Highlights Baxdela Activity Against...Read the original story

    Sunday Sep 17 | BioSpace

    ... infections) and is currently undergoing Phase 3 testing in patients with CABP (community-acquired bacterial pneumonia). Notably, Baxdela's high response rates were also observed against S. aureus isolates with mutations in the Quinolone Resistance ...

    Comment?

  12. Nabriva's pneumonia drug succeeds in late-stage trial, shares soarRead the original story w/Photo

    Monday Sep 18 | Channelnewsasia.com

    REUTERS: Nabriva Therapeutics Plc shares more than doubled in premarket trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia met the main goal of a late-stage study. The clinical trial, which was the first of two late-stage studies, showed that the company's drug, lefamulin, was as effective as the commonly used antibiotic moxifloxacin, meeting the main goal of the trial.

    Comment?

  13. Nabriva's pneumonia drug meets main goal in late-stage studyRead the original story w/Photo

    Monday Sep 18 | Reuters

    Nabriva Therapeutics Plc said on Monday its experimental treatment for community-acquired bacterial pneumonia met the main goal in a late-stage study, sending its shares up more than 70 percent in premarket trading. Community-acquired bacterial pneumonia is the leading cause of infectious death in the United States.

    Comment?

  14. Nabriva Therapeutics stock jumps 82% premarket on positive trial of pneumonia treatmentRead the original story w/Photo

    Monday Sep 18 | MarketWatch

    ... the company reported positive results from a late-stage trial of a treatment for community-acquired bacterial pneumonia, or CABP, the leading cause of infectious death in the U.S. The Dublin, Ireland-based company said its intravenous to oral ...

    Comment?

  15. Nabriva's Stock Explodes as Pneumonia Drug Wows in Two Phase III TrialsRead the original story

    Sunday Sep 17 | BioSpace

    Nabriva Therapeutics plc , a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced positive topline results from the lefamulin evaluation against pneumonia trial, which evaluated the safety and efficacy of intravenous to oral lefamulin in patients with community-acquired bacterial pneumonia . CABP is the leading cause of infectious death in the United States.

    Comment?

  16. North America Antifungal Drugs Market Regional, and country-level analysisRead the original story

    Friday Sep 15 | Emailwire.com

    ... Systemic fungal infections are those caused due to indigestion or inhalation of spores, leading to fungal pneumonia and diseases like candidaisis, meningitis, mucormycosis, etc. are caused by opportunistic fungus. Although majority of the fungal ...

    Comment?

  17. Why is my baby wheezing? Causes and treatmentsRead the original story w/Photo

    Sunday Sep 10 | Medical News Today

    ... can lead to a baby or infant wheezing. These include lower respiratory infections, such as bronchiolitis and pneumonia . Upper respiratory infections, also known as the common cold, can also cause noisy breathing but will not cause wheezing unless ...

    Comment?

  18. Boston Strategic Partners, Inc. is Utilizing Electronic Health Record...Read the original story w/Photo

    Thursday Sep 14 | PRWeb

    Boston Strategic Partners, Inc. , a life-sciences and healthcare consulting firm is utilizing its extensive experience with Health Economics and Outcomes Research and 'big data' to provide in-depth analysis of pneumonia patients characteristics, medication management, costs and laboratory testing. "Our focus is on providing detailed analysis to address pressing healthcare issues" - Fred Peyerl, Partner at Boston Strategic Partners, Inc. Boston Strategic Partners, Inc. , a life-sciences and healthcare consulting firm is utilizing its extensive experience with Health Economics and Outcomes Research and 'big data' to provide in-depth analysis of pneumonia patients characteristics, medication management, costs and laboratory testing.

    Comment?

  19. Kids with asthma are unnecessarily prescribed antibiotics: StudyRead the original story w/Photo

    Wednesday Sep 13 | Iol.co.za

    ... have asthma. "Antibiotics should only be given when there is clear evidence of a bacterial infection such as for pneumonia," Baan said. "However, we saw that, in children with asthma, most of the antibiotic prescriptions in children were intended ...

    Comment?

  20. Head-To-Head Review: Nabriva Therapeutics plc -Read the original story w/Photo

    Tuesday Sep 12 | Daily Political

    ... global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute ...

    Comment?